62587-73-9

Usage

Uses

1. Used in Pharmaceutical Applications:
(6R,7R)-3-[(4-Carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate is used as a pharmaceutical compound for its potential therapeutic properties. (6R,7R)-3-[(4-Carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate's unique structure may allow it to interact with specific biological targets, such as enzymes or receptors, which could be beneficial in the treatment of various diseases.
2. Used in Chemical Research:
In the field of chemical research, (6R,7R)-3-[(4-Carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate can be used as a starting material or a building block for the synthesis of other complex organic molecules. Its unique functional groups and stereochemistry make it an interesting candidate for further chemical modifications and exploration.
3. Used in Materials Science:
(6R,7R)-3-[(4-Carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate's structural features may also find applications in materials science, where it could be used to develop new materials with specific properties, such as improved mechanical strength, thermal stability, or chemical reactivity. (6R,7R)-3-[(4-Carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate's potential use in materials science would depend on its ability to form stable complexes or interact with other molecules in a controlled manner.

Therapeutic Function

Antibiotic

Antimicrobial activity

A semisynthetic parenteral cephalosporin supplied as the sodium salt. Activity against Ps. aeruginosa contrasts strikingly with poor activity against many other organisms. Anaerobic Gram-negative rods, Gram-positive rods and cocci are all resistant. It is stable to many β-lactamases, including the Ps. aeruginosa chromosomal enzyme, and is a poor substrate for the enzymes of Enterobacter spp. and Morg. morganii. It is slowly hydrolyzed by TEM β-lactamases and more rapidly by the enzymes of some carbenicillin-resistant strains of Ps. aeruginosa, with which distinct inoculum effects may be seen. A 500 mg intravenous bolus dose achieves a plasma concentration of c. 70 mg/L at the end of the injection; the corresponding intramuscular dose achieves a peak concentration of around 15 mg/L. The plasma half-life is 1.5 h. About 15–30% is protein bound. There is some metabolism of the drug, but the main route of excretion is via the kidneys, most appearing in the urine in the first 6 h. The plasma half-life is linearly related to creatinine clearance, rising to a mean of 10–13 h in patients where clearance was <10 mL/min, falling to around 2 h on hemodialysis. It is well tolerated, apart from nausea and vomiting in some subjects. It has been used in severe pseudomonas infections, usually in combination with an aminoglycoside, but treatment has been complicated on a number of occasions by the emergence of resistance or superinfection. It is available in Japan.

InChI:InChI=1/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)

Upstream product

• 957-68-6 7-Aminocephalosporanic acid 
• 63111-86-4 7-aminoceph-3-em-3-(4-carbamoylpyridiniomethyl)-4-carboxylate hydrochloride 
• 39925-38-7 2-phenyl-2-sulfoacetic acid 
• 1453-82-3 isonicotinamide 
• 60903-42-6 1-((6R)-7t-amino-2-carboxy-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-en-3-ylmethyl)-4-carbamoyl-pyridinium betaine 
• 39925-35-4 2-sulfo-2-phenylacetyl chloride 
• 41128-84-1 (6R)-3-acetoxymethyl-8-oxo-7t-((R)-2-phenyl-2-sulfo-acetylamino)-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 

Downstream Products

• 41444-66-0 Cefomonil 

Relevant academic research and scientific papers

Preparing method of Cefsulodin

The present invention discloses a Preparing method of Cefsulodin, comprising the steps of Intermediate D-alpha-Sulfophenylacetic acid or its salt with acylating agent to form mixed acid anhydride; Key intermediate 7-PACA dissolved in the solvent in the organic base or inorganic base under the a certain temperature to get 7-PACA solution; dropping mixed acid anhydride solution into 7- PACA solution, and to obtain the Cefsulodin after full reaction and treatment. The method adopts the new synthetic method to carry out the 7-position condensation reaction with the mixed acid anhydride method. The new method has mild condition, stable process and easy operation, which is helpful in solving unstable process problems caused by hard production of Sulfophenylacetyl chloride, unstable Acyl chloride, or the instability of the intermediate in the subsequent reaction.

Medicinal cefsulodin sodium compound and preparation method thereof

The invention relates to the technical field of medicine, in particular to a medicinal cefsulodin sodium compound and a preparation method thereof. The preparation method of the medicinal cefsulodin sodium compound includes steps: 1) preparation of 3-(4-pyridinecarboxamide-1-methylene)-7-amino-cephalosporanic acid; 2) preparation of D-sulfophenylacetyl chloride; 3) preparation of D-sulfocephalosporanic acid; 4) preparation of cefsulodin sodium. The technical defects of high cost, low safety and low yield of existing preparation methods are overcome; by adoption of a silicon reagent method for preparation of the cefsulodin sodium compound, racemate controllability, high safety, high yield and high quality are realized, starting materials are easy to acquire, reaction conditions of each step are mild, equipment requirements are low, a single solvent is adopted and convenient to recycle, the requirement on environment friendliness can be met, and the method is suitable for large-scale industrial production.